POINT Biopharma Global, Inc. (PNT)

NASDAQ: PNT · IEX Real-Time Price · USD
8.23
-0.12 (-1.44%)
Aug 17, 2022 4:00 PM EDT - Market closed
-1.44%
Market Cap 741.73M
Revenue (ttm) n/a
Net Income (ttm) -72.27M
Shares Out 90.12M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 224,966
Open 8.32
Previous Close 8.35
Day's Range 7.87 - 8.50
52-Week Range 4.25 - 11.72
Beta 0.07
Analysts Buy
Price Target 19.64 (+138.6%)
Earnings Date Aug 12, 2022

About PNT

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting prod... [Read more...]

Industry Biotechnology
Founded 2019
Employees 72
Stock Exchange NASDAQ
Ticker Symbol PNT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for PNT stock is "Buy." The 12-month stock price forecast is 19.64, which is an increase of 138.64% from the latest price.

Price Target
$19.64
(138.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights

Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release

POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on Au...

The event will prepare investors for the release of SPLASH's lead-in cohort efficacy data later this year by providing an overview of SPLASH's trial design.

POINT Biopharma to Participate in Upcoming Investor Conferences

INDIANAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing...

POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial

Mr. Horvath will lead the commercialization of POINT's pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer Radioligan...

POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program

A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004's Phase 1 therapeutic trial using 68 Ga-PNT6555 for imaging and 177 Lu-PNT6555 for therapy

POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update

POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled.

POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial

Clinical doses continue to be manufactured and shipped from the Company's Indianapolis, Indiana facility Clinical doses continue to be manufactured and shipped from the Company's Indianapolis, Indiana f...

POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting

POINT's PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68 Ga-PNT6555 for imaging and 177 Lu-PNT6555 for therapy is planned for summe...

POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update

Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial

POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption

POINT's industry-leading radioisotope supply chain enabled company to avoid delays POINT's industry-leading radioisotope supply chain enabled company to avoid delays

POINT Biopharma to Host Dosimetry Investor Education Event on March 29, 2022

Learn what “PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied” means in the context of radiopharmaceuticals

Is a Surprise Coming for POINT Biopharma (PNT) This Earnings Season?

POINT Biopharma (PNT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH trial...

Dosimetry data demonstrated PNT2002 has a ​ favorable and safe dosimetry profile in the patient population and dose regimen being studied

POINT Biopharma to Participate in Upcoming Virtual Investor Conferences

INDIANAPOLIS, Feb. 17, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing...

POINT Biopharma Provides Early-Stage Program Updates

Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022

POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs

Company's radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com

POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development

Dr. Vincent brings more than 25 years of pharma business development experience along with deep technical expertise including drug development relating to oncology/immuno-oncology, inflammatory, and aut...

POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes

Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join as VP Medical Affairs, and Michael Gottlieb (CCO) to depart the Compan...

POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)

POINT adds key technology to accelerate in-house no-carrier-added Lu-177 production POINT adds key technology to accelerate in-house no-carrier-added Lu-177 production

POINT Biopharma to Host Virtual Education Event on December 6, 2021

POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations

POINT Biopharma Reports Third Quarter 2021 Financial Results and Provides Business Update

Initiated randomization phase of Phase 3 SPLASH study of PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC)

POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement

Supply agreement enables development of POINT's next-generation Ac-225-based radioligand therapies. Supply agreement enables development of POINT's next-generation Ac-225-based radioligand therapies.

POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. Lu-177

POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations on Dec 6, 2021 – register online at https://hub.pointbiopharma.com/d...

ARTMS Inc. Announces Health Canada Submission for Ga-68 Production and Tri-party Collaboration to Advance Ga-68 Imagi...

BURNABY, British Columbia--(BUSINESS WIRE)--ARTMS Inc. (ARTMS), the global leader in developing and commercializing novel products enabling cyclotron production of the world's most needed medical radioi...

POINT Biopharma Posts New Preclinical Data, Exercises Option For FAP Inhibitor

Point Biopharma Global Inc (NASDAQ: PNT) has additional preclinical data from its fibroblast activation protein-alpha (FAP-alpha) inhibitor program, PNT2004.  The new data demonstrate rapid and persiste...